JPWO2020264333A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264333A5 JPWO2020264333A5 JP2021576921A JP2021576921A JPWO2020264333A5 JP WO2020264333 A5 JPWO2020264333 A5 JP WO2020264333A5 JP 2021576921 A JP2021576921 A JP 2021576921A JP 2021576921 A JP2021576921 A JP 2021576921A JP WO2020264333 A5 JPWO2020264333 A5 JP WO2020264333A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- drug substance
- pharmaceutical composition
- cbs
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093526A JP2025143275A (ja) | 2019-06-26 | 2025-06-04 | ホモシスチン尿症を処置するための酵素療法のためのｐｅｇ化シスタチオニンベータ合成酵素 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866810P | 2019-06-26 | 2019-06-26 | |
| US62/866,810 | 2019-06-26 | ||
| US202062983860P | 2020-03-02 | 2020-03-02 | |
| US62/983,860 | 2020-03-02 | ||
| PCT/US2020/039870 WO2020264333A1 (en) | 2019-06-26 | 2020-06-26 | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093526A Division JP2025143275A (ja) | 2019-06-26 | 2025-06-04 | ホモシスチン尿症を処置するための酵素療法のためのｐｅｇ化シスタチオニンベータ合成酵素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539077A JP2022539077A (ja) | 2022-09-07 |
| JPWO2020264333A5 true JPWO2020264333A5 (https=) | 2023-07-03 |
| JP2022539077A5 JP2022539077A5 (https=) | 2023-07-03 |
Family
ID=71670437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576921A Pending JP2022539077A (ja) | 2019-06-26 | 2020-06-26 | ホモシスチン尿症を処置するための酵素療法のためのｐｅｇ化シスタチオニンベータ合成酵素 |
| JP2025093526A Pending JP2025143275A (ja) | 2019-06-26 | 2025-06-04 | ホモシスチン尿症を処置するための酵素療法のためのｐｅｇ化シスタチオニンベータ合成酵素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093526A Pending JP2025143275A (ja) | 2019-06-26 | 2025-06-04 | ホモシスチン尿症を処置するための酵素療法のためのｐｅｇ化シスタチオニンベータ合成酵素 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12364765B2 (https=) |
| EP (2) | EP3990005B1 (https=) |
| JP (2) | JP2022539077A (https=) |
| KR (1) | KR20220044726A (https=) |
| CN (1) | CN114786712A (https=) |
| AU (1) | AU2020302079A1 (https=) |
| BR (1) | BR112021026292A2 (https=) |
| CA (1) | CA3145426A1 (https=) |
| CL (1) | CL2021003474A1 (https=) |
| DK (1) | DK3990005T3 (https=) |
| ES (1) | ES3058596T3 (https=) |
| FI (1) | FI3990005T3 (https=) |
| HR (1) | HRP20251579T1 (https=) |
| IL (1) | IL289245B2 (https=) |
| LT (1) | LT3990005T (https=) |
| MX (2) | MX2021015966A (https=) |
| PH (1) | PH12021553235A1 (https=) |
| PL (1) | PL3990005T3 (https=) |
| PT (1) | PT3990005T (https=) |
| RS (1) | RS67521B1 (https=) |
| SA (1) | SA521431197B1 (https=) |
| SI (1) | SI3990005T1 (https=) |
| SM (1) | SMT202600042T1 (https=) |
| WO (1) | WO2020264333A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3373922B1 (en) | 2015-11-09 | 2022-01-05 | The Regents of The University of Colorado, A Body Corporate | Compositions and methods for use in the treatment of homocystinuria |
| EP3612214A4 (en) | 2017-04-17 | 2021-01-20 | The Regents of the University of Colorado, A Body Corporate | ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA |
| HRP20251579T1 (hr) | 2019-06-26 | 2026-01-30 | Travere Therapeutics Switzerland Gmbh | Pegilirana cistationin beta sintaza za enzimsku terapiju za liječenje homocistinurije |
| MX2022002571A (es) * | 2019-09-03 | 2022-05-06 | Travere Therapeutics Switzerland Gmbh | Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina. |
| CN115721735A (zh) * | 2022-10-13 | 2023-03-03 | 呈诺再生医学科技(北京)有限公司 | Cbs基因在制备糖尿病视网膜病变治疗药物中的应用 |
| CN120610012A (zh) * | 2023-10-20 | 2025-09-09 | T&D诊断加拿大私人有限公司 | 用于诊断个体整体健康状况的标志物以及装置 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656425A (en) | 1993-08-17 | 1997-08-12 | Regents Of The University Of Colorado | Screening for mutations by expressing cDNA segments |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| US6653062B1 (en) * | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| AU2003251550A1 (en) | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| EP1396537A1 (en) | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| KR20060065663A (ko) | 2003-07-31 | 2006-06-14 | 안티캔서, 인코포레이티드 | 생체 내에서의 유효성 향상을 위한, ＰＥＧ-ｒＭＥＴ아제와조합된 ＰＬＰ의 용도 |
| US20070010492A1 (en) | 2005-07-11 | 2007-01-11 | Generale Robert J | Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| EP2510100B1 (en) * | 2009-12-09 | 2017-10-11 | CureVac AG | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CA2803668A1 (en) | 2010-07-01 | 2012-01-05 | Isis Innovation Limited | Treatment of cognitive disorders |
| US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) * | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| WO2015033279A1 (en) | 2013-09-04 | 2015-03-12 | Mahesh Kandula | Compositions and methods for the treatment of homocystinuria |
| AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| ES2865825T3 (es) | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Procedimientos y composiciones para inmunomodulación |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3373922B1 (en) | 2015-11-09 | 2022-01-05 | The Regents of The University of Colorado, A Body Corporate | Compositions and methods for use in the treatment of homocystinuria |
| BR112019000195A2 (pt) | 2016-07-07 | 2019-04-24 | Rubius Therapeutics, Inc. | composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno |
| EP3612214A4 (en) | 2017-04-17 | 2021-01-20 | The Regents of the University of Colorado, A Body Corporate | ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA |
| HRP20251579T1 (hr) | 2019-06-26 | 2026-01-30 | Travere Therapeutics Switzerland Gmbh | Pegilirana cistationin beta sintaza za enzimsku terapiju za liječenje homocistinurije |
| MX2022002571A (es) * | 2019-09-03 | 2022-05-06 | Travere Therapeutics Switzerland Gmbh | Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina. |
-
2020
- 2020-06-26 HR HRP20251579TT patent/HRP20251579T1/hr unknown
- 2020-06-26 LT LTEPPCT/US2020/039870T patent/LT3990005T/lt unknown
- 2020-06-26 SM SM20260042T patent/SMT202600042T1/it unknown
- 2020-06-26 PL PL20743019.0T patent/PL3990005T3/pl unknown
- 2020-06-26 AU AU2020302079A patent/AU2020302079A1/en active Pending
- 2020-06-26 EP EP20743019.0A patent/EP3990005B1/en active Active
- 2020-06-26 IL IL289245A patent/IL289245B2/en unknown
- 2020-06-26 DK DK20743019.0T patent/DK3990005T3/da active
- 2020-06-26 FI FIEP20743019.0T patent/FI3990005T3/fi active
- 2020-06-26 JP JP2021576921A patent/JP2022539077A/ja active Pending
- 2020-06-26 PH PH1/2021/553235A patent/PH12021553235A1/en unknown
- 2020-06-26 ES ES20743019T patent/ES3058596T3/es active Active
- 2020-06-26 SI SI202030699T patent/SI3990005T1/sl unknown
- 2020-06-26 KR KR1020227002804A patent/KR20220044726A/ko active Pending
- 2020-06-26 MX MX2021015966A patent/MX2021015966A/es unknown
- 2020-06-26 US US17/622,112 patent/US12364765B2/en active Active
- 2020-06-26 BR BR112021026292A patent/BR112021026292A2/pt unknown
- 2020-06-26 WO PCT/US2020/039870 patent/WO2020264333A1/en not_active Ceased
- 2020-06-26 RS RS20251214A patent/RS67521B1/sr unknown
- 2020-06-26 PT PT207430190T patent/PT3990005T/pt unknown
- 2020-06-26 CA CA3145426A patent/CA3145426A1/en active Pending
- 2020-06-26 EP EP25198152.8A patent/EP4663239A3/en active Pending
- 2020-06-26 CN CN202080060487.6A patent/CN114786712A/zh active Pending
-
2021
- 2021-12-16 MX MX2026001319A patent/MX2026001319A/es unknown
- 2021-12-23 SA SA521431197A patent/SA521431197B1/ar unknown
- 2021-12-24 CL CL2021003474A patent/CL2021003474A1/es unknown
-
2025
- 2025-06-04 JP JP2025093526A patent/JP2025143275A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3990005T3 (fi) | Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi | |
| KR950014915B1 (ko) | 탈시알로당단백-포함화합물 | |
| Cocohoba et al. | Valganciclovir: an advance in cytomegalovirus therapeutics | |
| KR940002820B1 (ko) | Hiv 감염 관련 질병의 치료를 위한 약제 조성물 | |
| KR20060120037A (ko) | Ｈｃｖ 감염 치료용 병용 요법 | |
| CA2376894C (en) | Pharmaceutical composition comprising a protein and an ectoine | |
| BRPI0610873A2 (pt) | tratamento de doenças hepáticas em que o ferro desempenhe um papel na patogênese | |
| AU2012292032A1 (en) | HCV immunotherapy | |
| JPWO2020264333A5 (https=) | ||
| KR100484695B1 (ko) | 제약 조성물 | |
| EP2604264B1 (en) | Pharmaceutical composition for treating viral diseases | |
| TW201630597A (zh) | 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途 | |
| CN1529612A (zh) | 治疗病毒感染的靶向给药组合物及方法 | |
| EP3965795B1 (en) | Stable albuvirtide compositions | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| JP7541054B2 (ja) | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 | |
| US20240293385A1 (en) | Combination therapy for treatment of liver diseases | |
| RU2022101609A (ru) | Пэгилированная цистатионин-бета-синтаза для ферментотерапии для лечения гомоцистинурии | |
| EP1553938B1 (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| US20030147850A1 (en) | Composition and methods for potentiating therapeutic effects of interferons | |
| US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
| RU2242243C2 (ru) | Композиции и способы потенцирования терапевтических эффектов интерферонов | |
| WO1991016916A1 (fr) | Agent antineoplastie | |
| CN104136038A (zh) | 体腔积液抑制剂 | |
| JPS623814B2 (https=) |